Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis

Alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis. It selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. We previously showed that regulatory T cell function is restored...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashani, Nicole, Kelland, Eve E., Vajdi, Borna, Anderson, Lauren M., Gilmore, Wendy, Lund, Brett T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581537/
https://www.ncbi.nlm.nih.gov/pubmed/34777337
http://dx.doi.org/10.3389/fimmu.2021.706278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581537/
https://www.ncbi.nlm.nih.gov/pubmed/34777337
http://dx.doi.org/10.3389/fimmu.2021.706278

Ejemplares similares